Research progress on regulation of Ang/Tie signaling pathway in the treatment of ocular neovascular diseases

Authors: Yang Jingyan,  Wei Wenbin
DOI: 10.3760/cma.j.cn115989-20220618-00283
Published 2024-05-10
Cite as Chin J Exp Ophthalmol, 2024, 42(5): 467-472.

Abstract                              [Download PDF] [Read Full Text]

The emergence of anti-vascular endothelial growth factor (VEGF) therapy has reduced the overall incidence of blindness from ocular neovascular disease.However, frequent intravitreal injections of anti-VEGF therapy are required, which places a significant burden to patients and affects long-term benefits.The angiopoietin (Ang)/tyrosine kinase with immunoglobulin-like and endothelial growth factor-like domains (Tie) pathways are identified as potentially therapeutic regulators for ocular neovascular disease, with additional benefits over anti-VEGF-A therapy.For ocular neovascular diseases, three molecules targeting the Ang/Tie pathway have been studied in clinical trials and the data released, in which faricimab, a bispecific immunoglobulin G1 antibody targeting VEGF-A and Ang-2, entered phase Ⅲ studies and met primary clinical endpoints, and two dosing regimens with prolonged treatment intervals (12 and 16 weeks) of faricimab showed reliable efficacy.Overall, the regulation of Ang/Tie pathway provides a new treatment option for ocular neovascular diseases, and it is necessary to deeply understand the mechanism of action of the pathway and accumulate more clinical data in the future.

Key words:

Retinal neovascularization; Anti-neovascularization; Ang/Tie pathway

Contributor Information

Yang Jingyan

Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology &

Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

Wei Wenbin

Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology &

Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

(Read 12 times, 1 visits today)